中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 6
Jun.  2018

Clinical features and prognosis of drug-induced liver injury: An analysis of 95 cases

DOI: 10.3969/j.issn.1001-5256.2018.06.022
Research funding:

 

  • Received Date: 2018-03-19
  • Published Date: 2018-06-20
  • Objective To analyze and summarize the clinical data of drug-induced liver injury (DILI) , and to investigate the clinical features and prognosis of DILI. Methods A retrospective analysis was performed for the clinical data of 95 patients with DILI who were admitted to The First Affiliated Hospital of Xi'an Medical University from February 2010 to February 2016, including sex, age, medication history, underlying diseases, clinical manifestation, laboratory and imaging findings, treatment, and prognosis. A logistic regression analysis was used to investigate the influencing factors for prognosis. Results Respiratory system diseases ranked first among the underlying diseases treated by drugs that caused DILI and accounted for 25. 26% (24/95) , and of all patients, 23. 16% (22/95) had tuberculosis. Among the drugs that caused DILI, traditional Chinese medicine ranked first and accounted for 44. 21% (42/95) , followed by antitubercular agents which accounted for 22. 11% (21/95) . DILI often occurred within 15-30 days of medication. Poor appetite was the most common symptom of DILI, and jaundice was the most common positive sign. Elevated alanine aminotransferase was the most common laboratory result of DILI.Acute hepatocellular injury type was the most common type of DILI. Most DILI patients had good prognosis, and patients with response to treatment accounted for 95. 79% (91/95) , including those who were improved or cured. Age (odds ratio [OR]= 0. 054, 95% confidence interval (CI) : 0. 002-0. 076, P = 0. 037) , alkaline phosphatase (OR = 0. 004, 95% CI: 0. 001-0. 006, P = 0. 043) , total bilirubin (OR = 0. 028, 95% CI: 0. 001-0. 039, P = 0. 035) , and direct bilirubin (OR = 0. 008, 95% CI: 0. 001-0. 014, P = 0. 036) were independent risk factors for prognosis. Conclusion DILI does not have specific clinical manifestations and can easily be missed or misdiagnosed. Clinicians should use drugs rationally, monitor the presence of hepatotoxicity, and strengthen the public health education on safe medication.

     

  • [1]BJRNSSON ES.Hepatotoxicity by drugs:The most common implicated agents[J].Int J Mol Sci, 2016, 17 (2) :224.
    [2]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
    [3]DEVARBHAVI H, PATIL M, REDDY VV, et al.Drug-induced acute liver failure in children and adults:Results of a single-centre study of 128 patients[J].Liver Int, 2017.[Epub ahead of print]
    [4]TESCHKE R, FRENZEL C, WOLFF A, et al.Drug induced liver injury:Accuracy of diagnosis in published reports[J].Ann Hepatol, 2014, 13 (2) :248-255.
    [5]CHALASANI NP, HAYASHIL PH, BONKOVSKY HL, et al.ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.
    [6]SGRO C, CLINARD F, OUAZIR K, et al.Incidence of drug-induced hepatic injuries:A French population-based study[J].Hepatology, 2002, 36 (2) :451-455.
    [7]BJRNSSON ES, BERGMANN OM, BJRNSSON HK, et al.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.
    [8]CHALASANI N, BONKOVSKY HL, FONTANA R, et al.Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352.
    [9]HU Q, LIU W, SHAO H.Research progress of pharmacotherapy drug-induced liver injury[J].Chin J Clin Pharmacol Ther, 2016, 21 (2) :231-236. (in Chinese) 胡琴, 刘维, 邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学, 2016, 21 (2) :231-236.
    [10]SUTTI S, TACKE F.Liver inflammation and regeneration in drug-induced liver injury:Sex matters[J].Clin Sci (Lond) , 2018, 132 (5) :609-613.
    [11]AMACHER DE.Female gender as a susceptibility factor for druginduced liver injury[J].Hum Exp Toxicol, 2014, 33 (9) :928-939.
    [12]LUCENA MI, ANDRADE RJ, KAPLOWITZ N, et al.Phenotypic characterization of idiosyncratic drug-induced liver injury:The influence of age and sex[J].Hepatology, 2009, 49 (6) :2001-2009.
    [13]ZHOU SM, JIA J.696 cases of drug-induced liver injury[J].Drug Eval, 2007, 4 (6) :442-443. (in Chinese) 周世明, 贾杰.696例药物性肝损害药物的临床分析[J].药品评价, 2007, 4 (6) :442-443.
    [14]LEISE MD, POTERUCHA JJ, TALWALKAR JA.Drug-induced liver injury[J].Mayo Clin Proc, 2014, 89 (1) :95-106.
    [15]ZHOU Y, YANG L, LIAO Z, et al.Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21, 789 patients[J].Eur J Gastroenterol Hepatol, 2013, 25 (7) :825-829.
    [16]ZHU Y, NIU M, CHEN J, et al.Hepatobiliary and pancreatic:Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients[J].J Gastroenterol Hepatol, 2016, 31 (8) :1476-1482.
    [17]LIU CH, ZHU CW.Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J].J Clin Hepatol, 2017, 33 (5) :829-832. (in Chinese) 刘成海, 朱春雾.中草药相关药物性肝损伤的流行特点、主要原因与诊断评估[J].临床肝胆病杂志, 2017, 33 (5) :829-832.
    [18]STICKEL F, SHOUVAL D.Hepatotoxicity of herbal and dietary supplements:An update[J].Arch Toxicol, 2015, 89 (6) :851-865.
    [19]TU C, JIANG BQ, ZHAO YL, et al.Comparison of processed and crude Polygoni Multiflori Radix induced rat liver injury and screening for sensitive indicators[J].Chin J Chin Mater Med, 2015, 40 (4) :654-660. (in Chinese) 涂灿, 蒋冰倩, 赵艳玲, 等.何首乌炮制前后对大鼠肝脏的损伤比较及敏感指标筛选[J].中国中药杂志, 2015, 40 (4) :654-660.
    [20]CHEN M, SUZUKI A, BORLAK J, et al.Drug-induced liver injury:Interactions between drug properties and host factors[J].J Hepatol, 2015, 63 (2) :503-514.
    [21]HUANG YS.Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury[J].J Chin Med Assoc, 2014, 77 (4) :169-173.
    [22]DAS S, BEHERA SK, XAVIER AS.Agreement among different scales for causality assessment in drug-induced liver injury[J].Clin Drug Investig, 2018, 38 (3) :211-218.
    [23]PETROS Z, KISHIKAWA J, MAKONNEN E, et al.HLA-B*57allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians[J].Front Pharmacol, 2017, 8:90.
    [24]RACHI C, PIPALIYA N, PATEL R, et al.Drug induced liver injury at a tertiary hospital in India:Etiology, clinical features and predictors of mortality[J].Ann Hepatol, 2017, 16 (3) :442-450.
    [25]MEDINA-CALIZ I, ROBLES-DIAZ M, GARCIA-MUOZ B, et al.Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J].J Hepatol, 2016, 65 (3) :532-542.
  • Cited by

    Periodical cited type(9)

    1. 陈红,赵莎莎,杨婉君. 慢性药物性肝损伤患者临床特征及转归分析. 肝脏. 2022(06): 679-682 .
    2. 刘欣妍,陈财福. 入园幼儿体检中丙氨酸转氨酶检测结果观察. 基层医学论坛. 2022(32): 86-88 .
    3. 王志民. 健肝乐颗粒联合保肝药物治疗抗精神病药物所致肝损伤的疗效及对生活质量的影响. 智慧健康. 2022(34): 83-86+90 .
    4. 韩建芳,胡锦兴,吴碧彤. 影响抗结核药物所致肝损伤预后的相关因素分析. 临床合理用药杂志. 2021(23): 170-172 .
    5. 陈鹏,周晓琳. 健肝乐颗粒治疗药物性肝损伤临床疗效与成本分析. 中国药业. 2020(04): 75-76 .
    6. 杨焕芝,徐艳琼,陈学平,李兴德,包金颖,方甜甜,张仲安,宋沧桑. 药物性肝损伤住院患者预后影响因素的研究. 中国药物评价. 2020(03): 222-227 .
    7. 赵向前,董菁. 药物性肝损伤患者的临床特点及CT影像学表现分析. 中国CT和MRI杂志. 2019(03): 83-86 .
    8. 李飞龙,黄赵刚,葛朝亮,夏泉,詹迪迪. 药物性肝损伤的临床特点及预后因素Logistic回归分析. 肝胆外科杂志. 2019(04): 258-262 .
    9. 田贞贞,刘永梅,刘芳,臧珊珊,马金彤,张桂珍,吕侯强,王英超. 抗结核治疗中导致肝损伤的危险因素分析. 解放军预防医学杂志. 2019(09): 90-92 .

    Other cited types(3)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2154) PDF downloads(381) Cited by(12)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return